Huntington’s Disease Inheritance and Genetic Testing: What Research Says About a 50% Risk

Huntington’s Disease Inheritance and Genetic Testing: What Research Says About a 50% Risk

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Research since the 1993 gene discovery shows that each child of a parent with Huntington’s disease has a 50% chance of inheriting the expanded HTT gene. The number of CAG repeats shapes the meaning of a result, but it gives probabilities, not a fixed date. Consumer DNA kits do not measure these repeats. Predictive testing works best through genetic counseling, and no disease-slowing therapy is approved yet.

What you’ll learn

• How the HTT gene and its CAG repeat cause Huntington’s disease, and what the “50% rule” really means
• What 36-39 repeats, 27-35 repeats and 40+ repeats mean for you and your children
• How predictive testing works, and why 23andMe and similar kits will not answer the question
• Where treatment stands in 2026, and what US and Canadian law does and does not protect

How Huntington’s disease is inherited: HTT, CAG repeats and the 50% rule

Huntington’s disease (HD) is a brain disorder that affects movement, thinking and mood. In 1993, an international research group found its cause. They located a gene on chromosome 4, now called HTT. Inside that gene sits a short DNA “word,” C-A-G, repeated many times in a row.

On typical chromosomes, the study found roughly 11 to 34 CAG copies. On HD chromosomes, the repeat was expanded, from about 42 to over 100 copies. Think of it like a word in a sentence that has been stuttered too many times. Past a certain length, the message starts to go wrong.

HD follows autosomal dominant inheritance (meaning one expanded copy, from either parent, is enough to cause risk). Each child of a person with the expansion has a 50% chance of inheriting it. That is about 50 out of 100 children, regardless of sex. There is no “silent carrier” state in the usual sense.

The GeneReviews clinical reference sorts repeat sizes into four bands:

CAG repeats	Band	What it means
26 or fewer	Normal	No HD from this gene copy
27-35	Intermediate	No HD in the person; may expand in children
36-39	Reduced penetrance	May or may not develop HD
40 or more	Full penetrance	Expected to develop HD over a normal life span

The repeat can also change between generations. The 1993 study showed expanded repeats were unstable when passed to children. This explains anticipation (symptoms tending to start earlier in later generations). Expansion happens far more often when the gene passes from a father. Contraction is more common through a mother.

Why does HD sometimes seem to “skip” a generation? A parent may have died young of other causes. Symptoms may have been labeled as another condition. Or a parent may have carried a reduced-penetrance or intermediate allele (gene version) that grew in the next generation.

If a relative has HD, a genetic counselor can draw your family tree with you. Find one at NSGC.org.

Section recap: HD is caused by an expanded CAG repeat in the HTT gene, and each child of a carrier has a 50% chance of inheriting it. Repeat length, not just presence, shapes what a result means.

How big is the risk? Penetrance, age of onset and what CAG length can and cannot predict

“Penetrance” means the chance that someone with a gene change actually develops the disease. For HD, penetrance depends on repeat length. At 40 or more repeats, HD is expected over a normal life span. At 36-39 repeats, some people never develop symptoms in their lifetime.

Symptoms typically begin around ages 40 to 50. After onset, median survival is about 15 to 18 years. These are averages across many families. A single person’s path can differ widely.

In 2004, Langbehn and colleagues built a model from a large multicentre sample. It estimates the chance of symptoms by a given age for each repeat length. Longer repeats predict earlier onset. But the model gives probabilities, not a date on a calendar. A genetic counselor can walk through these curves with a specific result.

Other genes also matter. The GeM-HD Consortium studied roughly 9,000 people with HD. Key findings:

• Onset timing tracks the uninterrupted CAG length in DNA, not the protein’s length
• Losing a small “CAA” interruption at the end of the repeat links to earlier onset
• Modifier genes involved in DNA repair, such as FAN1 and MSH3, shift onset by years

A 2025 study in Cell added a new layer. Researchers examined single brain cells from people who had HD. The inherited repeat, about 40 to 45 copies, kept growing inside striatal neurons (cells in a deep brain region controlling movement). Over decades, it reached roughly 100 to 500 or more copies. Neurons lost their normal identity only after passing about 150 repeats.

This suggests a two-step process. First, decades of slow and largely harmless growth. Then, rapid damage in each neuron once a threshold is crossed. An analogy is a slow leak that becomes a flood only after the dam gives way.

How common is HD? A 2012 meta-analysis found a pooled worldwide prevalence of about 2.71 per 100,000 people. In Europe, North America and Australia, it was about 5.70 per 100,000. In Asia, it was about 0.40 per 100,000. Put simply, roughly 6 in every 100,000 people in North America-type populations.

Bring these questions to a neurologist or genetic counselor before reading too much into any single number.

What does this mean for an at-risk family today? Three practical points follow from the research:

• A predictive result tells you whether the expansion is present, not exactly when symptoms will start
• Two people with the same count can have different onset ages, partly because of modifier genes
• The somatic-expansion finding is new science; it does not yet change how results are reported

Think of the repeat count as a long-range forecast. It tells you which season is coming, not the exact day of the first snow.

Section recap: Repeat length predicts onset as a probability, while modifier genes and somatic expansion help explain why people with similar results differ. No model can give an exact onset date.

Testing options: diagnostic, predictive, prenatal, and why 23andMe will not tell you

HD testing comes in three main forms. Each serves a different purpose.

1. Diagnostic testing. A neurologist orders this for someone who already has symptoms. It confirms whether HD explains them. It is often covered by insurance when medically necessary, but check your plan.
2. Predictive (presymptomatic) testing. This is for adults at risk who have no symptoms. International recommendations describe a careful, multi-step process.
3. Prenatal and pre-pregnancy options. These help people who want to avoid passing on the expansion. A genetic counselor explains the choices in detail.

The 2013 international recommendations set out the predictive-testing path:

• Testing should be voluntary, never pressured by family, partners or employers
• Pre-test genetic counseling comes first, with time to reflect
• Results should be given in person
• A companion or support person is recommended
• Follow-up after results should be offered
• Predictive testing of minors is not recommended without a medical benefit

GeneReviews adds that pre-test interviews assess motives, knowledge and the likely impact of results. They also include a neurological check. Some people choose to pay out of pocket for privacy. Others use insurance. Each choice has trade-offs that a counselor can explain.

Why consumer DNA tests do not answer this question. Kits such as 23andMe and AncestryDNA do not measure HTT CAG repeats. Their chips read single DNA letters at set positions. They cannot count how many times “CAG” repeats in a row. So a “clear” consumer report says nothing about HD risk.

Clinical labs size the repeat with methods designed for repeat counting. The 1993 discovery is what made this direct DNA testing possible. Think of it like weighing a parcel versus reading its label. A consumer kit reads labels; HD testing needs a scale.

For family planning, options include prenatal testing during pregnancy and embryo testing with IVF (PGT-M, preimplantation genetic testing for a single-gene condition). Some approaches let a person avoid learning their own status. These choices are complex, so plan them with a genetic counselor well before pregnancy.

Questions worth asking at a pre-test visit:

• How many visits does the process involve, and how long will it take?
• Who will give the result, and can a support person attend?
• How will the lab report the exact repeat count?
• What follow-up support is offered after results?
• How might the result affect relatives who have not tested?

Writing these down before the visit makes the conversation easier. Many people find the counseling sessions useful even if they later decide not to test.

Section recap: Predictive testing should go through structured genetic counseling, with results given in person. Consumer DNA kits like 23andMe do not measure HTT CAG repeats and cannot rule HD in or out.

Reading a result: what “positive”, “intermediate” and “reduced penetrance” really mean

Everyone has two copies of the HTT gene, one from each parent. So a lab report usually lists two repeat counts. The higher number is the one that matters most for HD risk.

An HD result is a count, not a yes-or-no answer. That makes it different from many genetic tests. Here is how each band is usually read:

Result	Meaning for the person	Meaning for children
40+ repeats	Expected to develop HD over a normal life span; timing uncertain	50% chance of inheriting the expansion
36-39 repeats	Reduced penetrance: may or may not develop HD, not certain	50% chance of inheriting; repeat may grow
27-35 repeats	Will not develop HD from this allele	Small risk the repeat expands, mainly via fathers
26 or fewer	Not affected by HD from this allele	No meaningful risk from this copy

The 36-39 band deserves special care. A result in this range is not a certain diagnosis of future disease. The Langbehn model shows a substantial chance of no symptoms within a normal life span. Results right at a band edge, such as 35 or 36, are worth discussing closely with the lab and counselor.

The 27-35 band confuses many families. The person tested will not develop HD from that allele. Yet the repeat can expand when passed on, especially from a father. This is one way HD can appear in a family with no known history.

A positive predictive result is not a diagnosis of current disease. In 2022, researchers proposed the Integrated Staging System (HD-ISS):

• Stage 0: carrying 40 or more repeats, with no detectable changes
• Stage 1: measurable biomarker changes, such as caudate or putamen volume loss on scans
• Stage 2: clinical motor and/or thinking signs
• Stage 3: decline in daily function

HD-ISS was built mainly for research and trial design. Still, it reframes a positive result as a biological stage, not active illness. It is like learning a storm is on the forecast while the sky is still clear.

Review any result in person with a neurologist or genetic counselor, not alone online.

Section recap: 40+ repeats means HD is expected over a normal life span, while 36-39 means reduced penetrance, not certainty. A positive result is Stage 0 biology, not current disease.

Before symptoms: monitoring, lifestyle evidence and clinical trials

No treatment has been proven to prevent or delay HD onset. That is the honest starting point. Still, gene-positive people have meaningful steps available.

Research shows that changes can start long before diagnosis. The TRACK-HD study followed premanifest carriers (people with the expansion but no diagnosis) for 36 months. Findings included:

• Brain volume loss in the caudate, putamen and white matter, years before diagnosis
• Subtle motor and thinking changes in carriers without a diagnosis
• Baseline imaging and CAG-age measures helped predict later onset

This work is the basis for monitoring programs and prevention-stage trials. Practical steps often discussed with clinicians include:

• A baseline neurological exam and regular follow-up
• Care at an HDSA Center of Excellence in the US or a Huntington Society of Canada-linked clinic
• Mental-health support before and after testing, as international guidance emphasizes follow-up
• Joining observational research or prevention trials listed on ClinicalTrials.gov

What about exercise, diet or brain training? These are sensible for general health. However, the studies in this review do not show that any lifestyle change delays HD onset. Be wary of supplements marketed as “protective.” None has regulatory approval for HD.

An analogy: monitoring is like a car’s regular inspection. It does not stop wear, but it catches changes early.

Monitoring also helps research move faster. HD-ISS was designed partly so trials can enroll people at Stage 0 or Stage 1. That is earlier than older trials, which mostly enrolled people with clear symptoms. Volunteers who join natural-history studies help build the data that future treatments will be judged against.

Talk with a neurologist about a monitoring plan that fits your situation.

Section recap: Brain changes can appear years before diagnosis, which makes monitoring and trial participation meaningful. No lifestyle step or supplement has been shown to delay onset.

Treatment in 2026: symptom drugs, the AMT-130 gene therapy data and huntingtin-lowering

Today’s approved drugs treat symptoms, not the underlying cause. The best-studied group is VMAT2 inhibitors (drugs that lower dopamine signaling to reduce chorea, the involuntary jerking movements).

Drug (brand)	FDA approval for HD chorea	Health Canada status (as of 2026-10-05)
Tetrabenazine (Xenazine)	2008-08-15, the first FDA-approved drug for any HD symptom	Available as Nitoman since 1996-12-09, plus generics
Deutetrabenazine (Austedo)	2017-04-03	No Drug Product Database record; not authorized in Canada
Valbenazine (Ingrezza)	2023-08-18 (tardive dyskinesia approval came first, 2017-04-11)	No Drug Product Database record; not authorized in Canada

Valbenazine’s HD approval rests on the KINECT-HD trial, led by Furr Stimming and colleagues. It was a phase 3, randomized, double-blind, placebo-controlled study. It enrolled roughly 128 adults for about 12 weeks. Valbenazine reduced chorea scores versus placebo, by roughly 3 points on average. Sleepiness was among the common side effects. Like the other VMAT2 drugs, it has not been shown to slow HD.

GeneReviews lists these drugs and neuroleptics as chorea options. It also notes that levodopa and MAO inhibitors should be avoided. Physical, speech and occupational therapy plus psychiatric care are also part of care.

AMT-130 gene therapy. AMT-130 is a one-time gene therapy from uniQure, delivered by brain surgery. In a company press release on 2025-09-24, the high dose showed 75% slower progression on the cUHDRS scale (p=0.003). It also showed 60% slower decline in Total Functional Capacity (p=0.033).

These numbers need careful framing:

• They are company-reported, not peer-reviewed
• The comparison group was an external control from natural-history data, not randomized
• About a dozen high-dose patients were involved

Regulatory status: AMT-130 is not approved by the FDA, Health Canada or any regulator. The company says the FDA agreed in mid-2026 that an accelerated-approval application was reasonable. The FDA also wants a confirmatory study well underway. As of the 2026-07-29 company update, the application was planned for Q3 2026. Whether it has been submitted could not be confirmed as of 2026-10-05. Four-year data were expected in September 2026; those results also could not be confirmed.

Huntingtin-lowering drugs. Tominersen is an antisense drug (a short genetic strand that reduces huntingtin protein). The GENERATION HD1 trial enrolled about 791 adults with manifest HD. Dosing stopped in March 2021 after an unfavorable benefit-risk review. Later analyses hinted at possible benefit in younger, less-affected people. That led to GENERATION HD2, with 301 participants. Its primary completion date was 2026-05-14, but results had not been located as of October 2026. Tominersen is not approved by the FDA or Health Canada.

An oral splicing modifier, votoplam (PTC518), was studied in the PIVOT-HD trial. The trial is listed as completed, but its results could not be confirmed here. The 2025 somatic-expansion research also points to slowing repeat growth as a future target.

Ask a neurologist or an HD clinic about current trial options and any change in approval status.

How to read HD treatment headlines. News about HD therapy is often hopeful and sometimes overstated. A few quick checks help:

• Was the comparison randomized, or an external control group?
• Is the data peer-reviewed, or a company press release?
• How many patients were treated? Small numbers mean wide uncertainty.
• Has a regulator actually approved the drug, or is a filing only planned?
• Does the drug slow the disease, or only ease a symptom like chorea?

These questions are like checking a weather forecast’s source before cancelling a trip. A strong headline is not the same as an approved treatment.

Section recap: Three VMAT2 drugs are FDA-approved for chorea, but only tetrabenazine is available in Canada. AMT-130 is not approved anywhere, and its encouraging data are company-reported with an external control.

Family implications: telling relatives, cascade conversations and family planning

HD affects the whole family tree. When one person is diagnosed, the risk ripples outward:

• Each child of the affected person has a 50% chance
• Each sibling of the affected person is at risk if a shared parent carried it
• A gene-positive at-risk person’s children each have a 50% chance

Testing one person can reveal another’s status. Imagine a grandchild tests positive while their at-risk parent has not tested. That result implies the parent also carries the expansion. The parent may not have wanted to know.

International guidance says the right not to know of relatives must be respected. That is why counselors encourage family conversations before testing. Testing is like opening one window in a shared house. Everyone inside feels the change in air.

Practical ways to start the conversation:

• Ask first whether now is a good time to talk about family health
• Explain that testing is being considered, and ask how the relative feels before any decision
• Make clear that the relative does not have to decide anything or test themselves
• Offer written resources or a joint counseling visit instead of all the details at once

For children, many families share information gradually and in age-appropriate words. Predictive testing of minors is generally not recommended. Children can decide for themselves as adults.

For family planning, options include prenatal testing, embryo testing with IVF, adoption and donor eggs or sperm. A genetic counselor can lay out each path without pressure.

Book a family session with a genetic counselor before any relative tests.

Section recap: Each child of a gene-positive person has a 50% chance of inheriting HD. Because one result can reveal another’s status, guidance stresses family discussion and the right not to know.

Insurance, work and privacy: GINA, Canada’s GNDA and the life-insurance gap

Fear of insurance problems stops many people from testing. The law protects some areas but not others.

United States: GINA (2008)

Covered by GINA	Not covered by GINA
Health insurance eligibility and premiums (Title I)	Life insurance
Employment decisions by employers with 15+ employees (Title II)	Disability insurance
	Long-term-care insurance
	People who already have symptoms (other laws apply)

Once symptoms appear, GINA no longer applies. Affordable Care Act (ACA) pre-existing-condition rules and the Americans with Disabilities Act (ADA) take over. Some families arrange life, disability or long-term-care coverage before predictive testing. This is a documented consideration, not personal advice. Some states have added protections, but details vary and change. Check your state’s current law with a professional.

Canada: GNDA (2017)

• It is an offence to require a genetic test as a condition of goods, services or contracts
• It is also an offence to require disclosure of existing results, including for insurance
• The Supreme Court of Canada upheld these rules in July 2020, in a 5-4 decision

An analogy: GINA is an umbrella that covers your head but not your feet. Know which parts stay exposed before you step outside.

A short checklist many families find useful:

• Review current life, disability and long-term-care policies before any predictive test
• Ask how test results will be stored and who can see them
• Learn which state or provincial rules apply, since local protections differ
• Keep copies of results in a secure personal file

Before testing, talk with a board-certified genetic counselor in the US (find one via NSGC) or a Canadian Association of Genetic Counsellors member. They can explain timing, privacy and insurance trade-offs.

Section recap: GINA protects US health insurance and most employment, but not life, disability or long-term-care insurance. Canada’s GNDA bars requiring genetic tests or results, including for insurance.

A practical path for families after a new diagnosis

A parent’s diagnosis often lands with no warning. The steps below summarize the research in this article into one order of action. They are not a substitute for clinical advice.

Step	What to do	Why it matters
1	Confirm the diagnosis in the affected parent	A confirmed repeat count anchors every later decision for relatives
2	Meet a genetic counselor before any relative tests	Guidance calls for pre-test counseling and time to reflect
3	Talk with siblings and adult children	One result can reveal another person’s status, so the right not to know matters
4	Review insurance before predictive testing	GINA does not cover life, disability or long-term-care insurance
5	Decide whether to test, and when	Testing is voluntary, and waiting is also a valid choice
6	If gene-positive, set up monitoring	Brain changes can appear years before diagnosis

Step 1 is easy to skip. Yet a confirmed count in the parent helps a lab and counselor read a relative’s result. It also checks that the family’s symptoms truly come from HD.

Step 5 deserves extra patience. Some people test soon after a diagnosis. Others wait years, or never test. International guidance treats each of these paths as legitimate. A test result cannot be “untaken,” so the timing should suit the person, not family pressure.

Step 6 also opens the door to research. Prevention-stage trials need gene-positive volunteers without symptoms. Joining one is optional and should follow a full discussion of risks.

Ask a genetic counselor to adapt this order to your family’s situation.

Section recap: Confirm the parent’s diagnosis, counsel before testing, talk with relatives and review insurance first. Testing is voluntary, and waiting is a valid choice.

Frequently asked questions

If a parent has Huntington’s disease, will their child develop it?

Each child has a 50% chance of inheriting the expanded HTT gene. Inheriting 40 or more repeats means HD is expected over a normal life span. Inheriting 36-39 repeats means reduced penetrance, so symptoms are possible but not certain. A genetic counselor can explain what applies to a specific family.

Will the children of a gene-positive person inherit HD?

Each child has a 50% chance of inheriting the expansion. The repeat may grow when passed on, especially from a father. Options such as embryo testing with IVF are available. Discuss them with a genetic counselor before pregnancy.

Will a positive HD test affect health or life insurance?

In the US, GINA bars health insurers from using genetic information. It does not cover life, disability or long-term-care insurance. In Canada, the GNDA bars requiring genetic tests or results for insurance contracts. Consider these gaps before testing.

Can an employer find out about a genetic test result?

In the US, GINA bars employers with 15 or more employees from using genetic information in employment decisions. In Canada, the GNDA bars requiring genetic tests or results as a contract condition. Paying privately for testing is one option some people choose. A genetic counselor can explain privacy safeguards.

Is a second opinion worth getting?

Yes, especially for results at a band edge, such as 35 or 36 repeats. Results in the 36-39 range also deserve careful review, because they are not a certain diagnosis. A second clinician can confirm the count and its meaning. HDSA Centers of Excellence and Huntington Society of Canada clinics are good places to ask.

Summary

• HD is caused by an expanded CAG repeat in the HTT gene, inherited in an autosomal dominant pattern with a 50% chance per child.
• Results fall into bands: 26 or fewer, 27-35, 36-39 (reduced penetrance, not certain) and 40 or more.
• Onset timing depends on repeat length, modifier genes and repeat growth inside neurons.
• Consumer DNA tests such as 23andMe do not measure HTT CAG repeats. Predictive testing should go through genetic counseling.
• Three VMAT2 drugs treat chorea in the US; AMT-130 is not approved anywhere.
• GINA does not cover life, disability or long-term-care insurance, so plan before testing.

Related reading: Neurogenetic Diseases category

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971-983. https://pubmed.ncbi.nlm.nih.gov/8458085/
2. Caldeira Brás I, Dawson J, Kay C, Caron NS, Hayden MR. Huntington Disease. GeneReviews (NCBI Bookshelf, University of Washington); initial posting 1998. https://www.ncbi.nlm.nih.gov/books/NBK1305/
3. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004;65(4):267-277. https://pubmed.ncbi.nlm.nih.gov/15025718/
4. Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell. 2019;178(4):887-900. https://pubmed.ncbi.nlm.nih.gov/31398342/
5. Handsaker RE, Kashin S, Reed NM, et al. Long somatic DNA-repeat expansion drives neurodegeneration in Huntington’s disease. Cell. 2025;188(3):623-639. https://pubmed.ncbi.nlm.nih.gov/39824182/
6. Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington’s disease: the Integrated Staging System. Lancet Neurol. 2022;21(7):632-644. https://pubmed.ncbi.nlm.nih.gov/35716693/
7. MacLeod R, Tibben A, Frontali M, et al. Recommendations for the predictive genetic test in Huntington’s disease. Clin Genet. 2013;83(3):221-231. https://pubmed.ncbi.nlm.nih.gov/22642570/
8. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study. Lancet Neurol. 2013;12(7):637-649. https://pubmed.ncbi.nlm.nih.gov/23664844/
9. Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27(9):1083-1091. https://pubmed.ncbi.nlm.nih.gov/22692795/
10. US FDA Drugs@FDA and Health Canada Drug Product Database. Regulatory status of tetrabenazine, deutetrabenazine and valbenazine (queried 2026-10-05). https://www.accessdata.fda.gov/scripts/cder/daf/ ; https://health-products.canada.ca/dpd-bdpp/
11. Furr Stimming E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-HD). Lancet Neurol. 2023;22(6):494-504. https://pubmed.ncbi.nlm.nih.gov/37210099/
12. McColgan P, Thobhani A, Boak L, et al. Tominersen in adults with manifest Huntington’s disease. N Engl J Med. 2023;389(23):2203-2214. https://pubmed.ncbi.nlm.nih.gov/38055260/
13. uniQure N.V. AMT-130 press releases (2025-09-24 topline; 2026-07-29 company update). https://uniqure.gcs-web.com/ ; https://www.biospace.com/press-releases/uniqure-announces-second-quarter-2026-financial-results-and-provides-company-update
14. Genetic Information Nondiscrimination Act of 2008 (NHGRI summary); Genetic Non-Discrimination Act, S.C. 2017, c. 3; Reference re Genetic Non-Discrimination Act, 2020 SCC 17. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination ; https://laws-lois.justice.gc.ca/eng/acts/G-2.5/ ; https://scc-csc.lexum.com/scc-csc/scc-csc/en/item/18435/index.do

---

Last updated: 2026-10-05

Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article aggregates 14 sources (tier 1=10 / tier 2=3 / tier 3=1). Sources include peer-reviewed papers indexed in PubMed and the GeneReviews clinical reference. They also include records from the US FDA and Health Canada. Legal sources include GINA summaries from NHGRI and a Supreme Court of Canada ruling.

Editor in charge: Yu Mizuno, a non-physician research editor. The editor does not hold medical or genetic counseling credentials.

This article is for educational purposes only. It is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-neurogenetic/huntingtons-disease-inheritance-cag-repeat